<DOC>
	<DOCNO>NCT00804622</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability effectiveness 12 week treatment telbivudine 600 mg daily plus tenofovir DF 300 mg daily ( QD ) take together versus tenofovir DF 300 mg daily ( QD ) versus telbivudine 600 mg monotherapy daily ( QD ) . This open-labeled , active control , viral kinetics study mean subject study doctor know study drug subject assign . This study open male female subject , &lt; 40 year age , infect HBV least 6 month receive oral treatment HBV .</brief_summary>
	<brief_title>Effects Telbivudine Tenofovir Disproxil Fumarate Kinetics Hepatitis B Virus DNA Chronic Hepatitis B ( CHB )</brief_title>
	<detailed_description>The primary goal therapy chronic hepatitis B ( CHB ) suppression viral replication . Long-term suppression serum HBV DNA likely reduce progression cirrhosis hepatic decompensation decrease risk hepatocellular carcinoma . Conventional treatment chronic hepatitis B limit low rate sustain hepatitis B virus DNA suppression hepatitis B e antigen ( HBeAg ) seroconversion , increase rate drug resistance oral agent , poor tolerability interferon . Currently , several nucleoside/nucleotide analogue available treatment CHB . Typically , treatment continue indefinitely since discontinuation usually associate relapse . However , safety implication relate long term treatment still unknown . Previously publish study use combination ( peginterferon alpha-2a + lamivudine ) ( Marcellin 2004 ; Lau 2005 ; Janssen 2005 ) show combination potent HBeAg loss end dosing , either agent use monotherapy ; off-treatment difference , however , persist . There treatment paradigm yet combination therapy two nucleoside analogue use treatment-naive patient . In summary , unmet need improve anti-HBV therapy still several controversy treatment option , potential role combination therapy versus monotherapy optimal duration therapy , among others . Clinical trial underway answer question . This study aim ass whether combination therapy telbuvudine tenofovir DF superior antiviral efficacy compare tenofovir DF telbuvidine monotherapy . The study also determine safety combination telbivudine tenofovir disoproxil fumarate patient chronic hepatitis B . Patients immunotolerant phase CHB include study . This phase characterize high viremia normal transaminase . Since patient consider candidate CHB therapy accord international guideline ( Lok et al 2007 ) , treatment discontinuation 12 week raise unethical implication . REFERENCES : 1 . Janssen HL , van Zonneveld M , Senturk H , Zeuzem S , Akarca US , Cakaloglu Y , Simon C , So TM , Gerken G , de Man RA , Niesters HG , Zondervan P , Hansen B , Schalm SW ; HBV 99-01 Study Group ; Rotterdam Foundation Liver Research . Pegylated interferon alfa-2b alone combination lamivudine HBeAg-positive chronic hepatitis B : randomised trial . Lancet . 2005 Jan 8-14 ; 365 ( 9454 ) :123-9 . 2 . Lau GK , Piratvisuth T , Luo KX , Marcellin P , Thongsawat S , Cooksley G , Gane E , Fried MW , Chow WC , Paik SW , Chang WY , Berg T , Flisiak R , McCloud P , Pluck N ; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group . Peginterferon Alfa-2a , lamivudine , combination HBeAg-positive chronic hepatitis B. N Engl J Med . 2005 Jun 30 ; 352 ( 26 ) :2682-95 . 3 . Lok AS , McMahon BJ . ( 2007 ) Chronic hepatitis . Hepatology 45 ( 2 ) :507-39 . 4 . Marcellin P , Lau GK , Bonino F , Farci P , Hadziyannis S , Jin R , Lu ZM , Piratvisuth T , Germanidis G , Yurdaydin C , Diago M , Gurel S , Lai MY , Button P , Pluck N ; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group . Peginterferon alfa-2a alone , lamivudine alone , two combination patient HBeAg-negative chronic hepatitis B. N Engl J Med . 2004 Sep 16 ; 351 ( 12 ) :1206-17 . Primary objective : The primary objective study characterize reduction HBV DNA level Baseline week 12 telbivudine plus tenofovir DF combination therapy versus telbivudine tenofovir DF monotherapy . Secondary objective : Secondary objective study include describe follow telbivudine plus tenofovir DF combination therapy versus telbivudine tenofovir DF monotherapy : 1. reduction HBV DNA level Baseline Weeks 2 , 4 , 8 2. characterization early viral kinetics estimation various parameter efficiency block new virus production , half-lives free virion infect heptocytes 3 . % patient PCR negative Week 12 ( define &lt; 25 copies/mL ) 4 . % patient achieve HBeAg loss HBeAg seroconversion Week 12 5. safety Exploratory objective : 1 . To explore HBeAg HBsAg level treatment period additional potential predictor efficacy . 2 . To explore additional potential early serological immunological marker prediction efficacy safety .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Patients must meet follow inclusion criterion screen eligible participation study . 1 . Chronic HBV infection , define positive serum HBsAg least 6 month , HBsAg positive &gt; 3 month negative IgM antiHBc positive IgG antiHBc 2 . Age &lt; 40 year old 3 . HBeAg positive 4 . HBV DNA ≥ 10^7 copies/mL Abbott realtime PCR 5 . ALT ≤ 1 ULN 6 . Willing able provide write informed consent 7 . Negative serum βHCG ( female childbearing potential ) 8 . Calculated creatinine clearance ≥ 70 mL/min follow formula : ( 140 age year ) x ( body weight [ kg ] ) / ( 72 ) x ( serum creatinine [ mg/dl ] ) [ Note : multiply estimate rate 0.85 woman ] 9 . Hemoglobin ≥ 10 g/dL 10 . Neutrophils ≥ 1,500 /mm^3 11 . No prior oral HBV therapy ( e.g. , nucleotide and/or nucleoside therapy investigational agent HBV infection ) 12 . Is willing able comply study drug regimen study procedures requirement 13 . Is willing able provide write informed consent study assessment perform . Patients exclude study criterion : 1 . Decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2 × ULN , PT &gt; 1.2 × ULN , platelets &lt; 150,000/mm3 , serum albumin &lt; 3.5 g/dL , prior history clinical hepatic decompensation ( e.g . ascites , jaundice , encephalopathy , variceal hemorrhage ) . 2 . Received interferon ( pegylated ) therapy within 6 month screen visit 3. αfetoprotein &gt; 50 ng/mL 4 . Evidence hepatocellular carcinoma ( HCC ) 5 . Coinfection HCV ( serology ) , HIV , HDV . 6 . Significant renal , cardiovascular , pulmonary , neurological disease . 7 . Received solid organ bone marrow transplantation . 8 . Is currently receive therapy immunomodulators ( e.g. , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent susceptible modify renal excretion . 9 . Has proximal tubulopathy . 10 . Use investigational drug time enrollment , within 30 day 11 . History hypersensitivity study drug drug similar chemical class 12 . Is pregnant breastfeed . Women childbearing potential must negative serum β HCG Screening . 13 . Is woman childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/m 6 week post surgical bilateral oophorectomy without hysterectomy OR use one follow acceptable method contraception : surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) . 14 . Patient concurrent medical social condition likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study . 15 . Patient currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year . Please refer Appendix 3 . 16 . Patient medical condition require prolonged frequent use systemic acyclovir famciclovir . Please refer Appendix 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HBeAg positive compensate chronic hepatitis B</keyword>
</DOC>